The SGLT2 inhibitor empagliflozin reduces hospitalization for heart failure in patients with HFrEF via a mechanism that goes beyond glycemic control. The primary proposed hemodynamic mechanism involves:
- A Inhibition of myocardial glucose uptake, forcing a switch to ketone body metabolism that is more oxygen-efficient
- B Diuretic and natriuretic effect via proximal tubule NHE3 inhibition plus osmotic glucose-driven water excretion, reducing preload and afterload without neurohormonal activation ✓
- C Direct inhibition of cardiac sodium-hydrogen exchanger NHE1, reducing intracellular Ca2+ overload in cardiomyocytes
- D Reduction in plasma aldosterone through inhibition of tubular renin secretion
Explanation
SGLT2 inhibitors' cardiac benefits are multifactorial but the primary hemodynamic mechanism is volume reduction: they produce osmotic glucosuria (dragging water) and, importantly, also inhibit NHE3 (sodium-hydrogen exchanger 3) in the proximal tubule, causing natriuresis. This reduces plasma volume and preload without activating RAAS or sympathetic nervous system (unlike loop diuretics that trigger neurohormonal rebound). Additionally, they raise hematocrit, reduce visceral adiposity, and may shift myocardial fuel utilization. The cardiac NHE1 hypothesis (option C) is proposed but less established in humans. EMPEROR-Reduced and DAPA-HF trials confirmed benefit regardless of diabetes status.
Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.